Invenra and Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody-drug conjugates (ADCs) and complex biologics, announced today a strategic collaboration to advance the development of…
Invenra has launched its T-Body™ trispecific antibody platform, a next-generation technology designed to direct correct chain pairing and afford high expression and assembly efficiency in a variety of antibody constructs,…
Invenra launched its B-Body Express Antibody Expression service, which enables biotechnology and pharmaceutical companies to rapidly access the company’s B-Body bispecific antibody platform, the company announced recently. “Advancing bispecific programs…
Invenra and Orion Corporation, a globally operating pharmaceutical company, announced recently that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform. “This collaboration highlights…
Invenra announced today that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designations (ODD) to its innovative bispecific antibody, INV724, developed for…
Invenra is partnering with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients, the company announced today. According to a release, the…
Invenra has expanded its discovery and licensing collaboration with Exelixis to include an additional 20 oncology targets, the company announced today. According to a release, the collaboration builds on the…
Invenra and the Wisconsin Alumni Research Foundation have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, the company announced recently. “This…
Invenra will collaborate with Merck, a pharmaceutical company, to discover fully human therapeutic antibodies against an unnamed target of interest to Merck, the company announced recently. “We are excited to…
Invenra has teamed up with Australian biomedical research and development center QIMR Berghofer Medical Research Institute to identify and characterize a panel of fully human therapeutic monoclonal antibodies against a novel…
